Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness and Safety of Autogene Cevumeran, Atezolizumab, and mFOLFIRINOX in Patients with Resected Pancreatic Cancer

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the treatment of pancreatic ductal adenocarcinoma, a type of cancer that starts in the ducts of the pancreas. The study will compare the effectiveness and safety of a combination treatment involving Autogene Cevumeran and Atezolizumab with a chemotherapy regimen called mFOLFIRINOX, against mFOLFIRINOX alone. Autogene Cevumeran is a type of gene therapy that uses mRNA, a molecule that carries genetic information, to help the body recognize and fight cancer cells. Atezolizumab is an immunotherapy drug that helps the immune system attack cancer cells. mFOLFIRINOX is a combination of chemotherapy drugs used to treat pancreatic cancer.

The purpose of this study is to evaluate how well the combination of Autogene Cevumeran, Atezolizumab, and mFOLFIRINOX works compared to mFOLFIRINOX alone, by looking at how long patients remain free of cancer after treatment. Participants in the study will be randomly assigned to receive either the combination treatment or mFOLFIRINOX alone. The study will last for up to 12 months, during which participants will receive their assigned treatment and be monitored for any side effects and the effectiveness of the treatment.

Throughout the study, participants will undergo regular check-ups, including imaging tests like MRI or CT scans, to assess the status of their cancer. The study aims to provide valuable information on whether adding Autogene Cevumeran and Atezolizumab to the standard mFOLFIRINOX treatment can improve outcomes for patients with pancreatic ductal adenocarcinoma. This research could potentially lead to new treatment options for this type of cancer.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization

    Upon joining the study, you will be randomly assigned to one of two groups. One group will receive a combination of autogene cevumeran, atezolizumab, and mFOLFIRINOX, while the other group will receive mFOLFIRINOX alone. This process is called randomization and ensures that each participant has an equal chance of being placed in either group.

  2. Step 2

    Treatment administration

    If you are in the group receiving the combination treatment, you will receive autogene cevumeran and atezolizumab along with mFOLFIRINOX. mFOLFIRINOX includes medications such as calcium folinate, fluorouracil, oxaliplatin, and irinotecan hydrochloride. These medications are administered through an intravenous infusion, which means they are given directly into your bloodstream through a vein.

    The specific dosages and frequency of administration will be determined by the study protocol and your healthcare team. The duration of the treatment phase will be specified by the study and communicated to you by your healthcare provider.

  3. Step 3

    Monitoring and follow-up

    Throughout the study, your health will be closely monitored. This includes regular check-ups, blood tests, and imaging scans such as CT or MRI to assess your condition and the effectiveness of the treatment.

    You will also be asked to report any side effects or changes in your health to the study team. This information is crucial for evaluating the safety and efficacy of the treatment.

  4. Step 4

    End of study participation

    At the end of the study, you will have a final evaluation to assess your overall health and the outcomes of the treatment. This may include additional tests and consultations with your healthcare team.

    You will be informed about the results of the study and any potential next steps in your treatment plan.

Who can join the trial?

8 criteria

  • Diagnosis of a resectable **PDAC** tumor before surgery. **PDAC** stands for **Pancreatic Ductal Adenocarcinoma**, a type of pancreatic cancer.
  • Confirmation of **PDAC** through a test called a histological diagnosis, which examines tissue under a microscope.
  • The cancer must be staged as **T1-T3, N0-N2, and M0** according to the **American Joint Committee on Cancer (AJCC) Staging Manual, 8th edition**. This means the tumor is of a certain size and has not spread to distant parts of the body.
  • The tumor must have been completely removed through surgery, which is referred to as a **macroscopically complete (R0 or R1) resection**.
  • No signs of the disease should be present after surgery, as determined by the doctor. This includes reviewing all available data such as imaging tests like **CT** (Computed Tomography) or **MRI** (Magnetic Resonance Imaging) scans, blood tests, and clinical findings within 28 days before starting the study.
  • A blood test measuring **Carbohydrate Antigen 19-9 (CA19-9)** levels must be done within 14 days before starting the study treatment. **CA19-9** is a substance that can be found in higher levels in people with certain types of cancer.
  • Both male and female participants are eligible.
  • Participants from vulnerable populations are also eligible.

Who cannot join the trial?

11 criteria

  • Patients with any other type of cancer besides pancreatic ductal adenocarcinoma cannot participate.
  • Patients who have had another cancer within the last 5 years, except for skin cancer that is not melanoma or in situ cervical cancer, are excluded.
  • Patients with serious heart problems, such as heart failure or a recent heart attack, are not eligible.
  • Patients with uncontrolled high blood pressure cannot join the study.
  • Patients with active infections, including HIV, hepatitis B, or hepatitis C, are excluded.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients with known allergies to the study drugs or similar drugs are not eligible.
  • Patients who have received another investigational drug within the last 4 weeks are excluded.
  • Patients with a history of autoimmune diseases, which are conditions where the immune system attacks the body, cannot participate.
  • Patients with a history of organ transplant are not eligible.
  • Patients with any condition that the study doctors believe would make it unsafe for them to participate are excluded.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Autogene Cevumeran

    is a type of personalized cancer vaccine. It is designed to help your immune system recognize and attack cancer cells more effectively. This vaccine is made specifically for each patient, using information from their own tumor to create a treatment that targets their cancer.

  • Atezolizumab

    is an immunotherapy drug that helps your immune system fight cancer. It works by blocking a protein that stops the immune system from attacking cancer cells. By doing this, atezolizumab helps your body’s natural defenses to better recognize and destroy cancer cells.

  • mFOLFIRINOX

    is a combination of chemotherapy drugs used to treat cancer. It includes several different medications that work together to stop cancer cells from growing and dividing. This treatment is often used to help shrink tumors and slow down the progression of the disease.

What is already known about the treatment

  • Autogene Cevumeran

    Autogene Cevumeran is administered as an injection and is currently being studied in clinical trials for its effectiveness in treating pancreatic ductal adenocarcinoma, a type of pancreatic cancer. It is not yet widely used in medicine, as it is still under investigation. The main purpose of this medication is to help prevent the return of cancer after surgery. It works by stimulating the immune system to recognize and attack cancer cells. Autogene Cevumeran is classified as an immunotherapy, which means it helps the body's natural defenses fight cancer.

  • Atezolizumab

    Atezolizumab is given as an intravenous infusion and is already approved for use in various cancers, but it is being tested in combination with other treatments for pancreatic ductal adenocarcinoma. It is used to help the immune system detect and destroy cancer cells. Atezolizumab works by blocking a protein that prevents the immune system from attacking cancer cells. It is classified as a checkpoint inhibitor, a type of immunotherapy that enhances the body's immune response against cancer.

  • mFOLFIRINOX

    mFOLFIRINOX is a combination of chemotherapy drugs administered through an intravenous infusion. It is a standard treatment for pancreatic ductal adenocarcinoma and is used to kill cancer cells and prevent them from growing. The combination includes several drugs that work together to interfere with the DNA of cancer cells, stopping their growth and division. mFOLFIRINOX is classified as a chemotherapy regimen, which is a treatment that uses drugs to destroy cancer cells.

Investigated diseases

Pancreatic ductal adenocarcinoma – This is a type of cancer that begins in the ducts of the pancreas, which is an organ located behind the stomach. It typically starts when cells in the pancreatic ducts develop mutations in their DNA, causing them to grow uncontrollably and form a tumor. As the disease progresses, the tumor can invade nearby tissues and organs, such as the stomach, liver, and intestines. It may also spread to distant parts of the body through the bloodstream or lymphatic system. The disease often grows silently, with symptoms appearing only after it has advanced. Common symptoms include jaundice, weight loss, and abdominal pain.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2022-502404-73-00Protocol codeGO44479Estimated enrolment566 patientsSponsorGenentech Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.